| Entry |
|
|---|
| Name |
Eslicarbazepine acetate (USAN);
Zebinix (TN);
Aptiom (TN) |
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C17H16N2O3
|
|---|
| Exact mass |
296.1161
|
|---|
| Mol weight |
296.3205
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG03199 Antiepileptic agent
DG02034 Carboxamide antiepileptic
Metabolizing enzyme inhibitor
DG01933 CYP2C19 inhibitor
Metabolizing enzyme inducer
DG02853 CYP3A/CYP3A4 inducer
DG01635 CYP3A4 inducer
|
|---|
| Remark |
| Product (DG00848): | D09612<US> |
|
|---|
| Efficacy |
Antiepileptic |
|---|
| Comment |
Carboxamide derivative
Adjunctive therapy for adults with partial-onset seizures
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
CYP inhibition: CYP2C19 [HSA: 1557]
CYP induction: CYP3A4 [HSA: 1576]
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N03 ANTIEPILEPTICS
N03A ANTIEPILEPTICS
N03AF Carboxamide derivatives
N03AF04 Eslicarbazepine
D09612 Eslicarbazepine acetate (USAN) <US>
USP drug classification [BR:br08302]
Anticonvulsants
Sodium Channel Agents
Eslicarbazepine
D09612 Eslicarbazepine acetate (USAN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG03199 Antiepileptic agent
DG02034 Carboxamide antiepileptic
DG00848 Eslicarbazepine
D09612 Eslicarbazepine acetate
Metabolizing enzyme inhibitor
DG01933 CYP2C19 inhibitor
DG00848 Eslicarbazepine
D09612 Eslicarbazepine acetate
Metabolizing enzyme inducer
DG02853 CYP3A/CYP3A4 inducer
DG01635 CYP3A4 inducer
DG00848 Eslicarbazepine
D09612 Eslicarbazepine acetate
Drug classes [BR:br08332]
Neuropsychiatric agent
DG03199 Antiepileptic agent
D09612 Eslicarbazepine acetate
Target-based classification of drugs [BR:br08310]
Ion channels
Voltage-gated ion channels
Sodium channels
SCN1A
D09612 Eslicarbazepine acetate (USAN) <US>
SCN2A
D09612 Eslicarbazepine acetate (USAN) <US>
SCN3A
D09612 Eslicarbazepine acetate (USAN) <US>
SCN4A
D09612 Eslicarbazepine acetate (USAN) <US>
SCN5A
D09612 Eslicarbazepine acetate (USAN) <US>
SCN8A
D09612 Eslicarbazepine acetate (USAN) <US>
SCN9A
D09612 Eslicarbazepine acetate (USAN) <US>
SCN10A
D09612 Eslicarbazepine acetate (USAN) <US>
SCN11A
D09612 Eslicarbazepine acetate (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D09612
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D09612
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D09612
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D09612
Drug groups [BR:br08330]
Neuropsychiatric agent
DG03199 Antiepileptic agent
DG02034 Carboxamide antiepileptic
DG00848 Eslicarbazepine
Metabolizing enzyme inhibitor
DG01933 CYP2C19 inhibitor
DG00848 Eslicarbazepine
Metabolizing enzyme inducer
DG02853 CYP3A/CYP3A4 inducer
DG01635 CYP3A4 inducer
DG00848 Eslicarbazepine
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 22
1 C8y C 22.4000 -25.4100
2 N1y N 23.6600 -24.7800
3 C8y C 24.9200 -25.4100
4 C8y C 25.2000 -26.7400
5 C8y C 22.1200 -26.8100
6 C1x C 24.3600 -27.8600
7 C1y C 22.9600 -27.8600
8 C8x C 21.3500 -24.4300
9 C8x C 20.0200 -24.9200
10 C8x C 19.7400 -26.2500
11 C8x C 20.7900 -27.2300
12 C8x C 26.6000 -27.0900
13 C8x C 27.5800 -26.1100
14 C8x C 27.2300 -24.7800
15 C8x C 25.8300 -24.3600
16 C5a C 23.6600 -23.3800
17 O5a O 22.4700 -22.6800
18 N1a N 24.8500 -22.6800
19 O7a O 22.3300 -29.1200
20 C7a C 20.9300 -29.1200
21 O6a O 20.2300 -27.9076
22 C1a C 20.2300 -30.3324
BOND 24
1 3 4 1
2 1 5 1
3 4 6 1
4 2 3 1
5 5 7 1
6 1 2 1
7 6 7 1
8 1 8 2
9 8 9 1
10 9 10 2
11 10 11 1
12 5 11 2
13 4 12 2
14 12 13 1
15 13 14 2
16 14 15 1
17 15 3 2
18 2 16 1
19 16 17 2
20 16 18 1
21 7 19 1 #Down
22 19 20 1
23 20 21 2
24 20 22 1
|
|---|
